MED12 and leiomyosarcoma: Furthermore, mutations in MED12 have been identified in rare fibroid variations, including atypical, cellular, and lipoleiomyomas in addition to leiomyosarcomas and smooth muscle tumors with uncertain malignant potential [7, 52].